New NASH drug candidate tested in healthy volunteers for first time
NCT ID NCT06308874
First seen Jan 03, 2026 · Last updated Jun 09, 2026 · Updated 25 times
Summary
This early-phase trial tested a single dose of J2H-1702 in 16 healthy women aged 19-45 to see if it is safe and how the body processes it. The study did not involve people with NASH (a liver disease) and was designed to gather basic safety and drug-level information. Results will help decide if further studies in patients are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
Conditions
Explore the condition pages connected to this study.